1
Clinical Trials associated with Melan-A analog peptide + Tyrosinase YMD peptide Vaccine Adjuvanted with CpG and Montanide(Centre Hospitalier Universitaire Vaudois)Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients With CpG7909, Tumor Antigenic Peptides and Montanide
The purpose of this study is to determine whether vaccination with tumor antigenic peptides and both CpG and Montanide adjuvants can induce an immune response in melanoma patients and to assess the safety of this vaccination.
100 Clinical Results associated with Melan-A analog peptide + Tyrosinase YMD peptide Vaccine Adjuvanted with CpG and Montanide(Centre Hospitalier Universitaire Vaudois)
100 Translational Medicine associated with Melan-A analog peptide + Tyrosinase YMD peptide Vaccine Adjuvanted with CpG and Montanide(Centre Hospitalier Universitaire Vaudois)
100 Patents (Medical) associated with Melan-A analog peptide + Tyrosinase YMD peptide Vaccine Adjuvanted with CpG and Montanide(Centre Hospitalier Universitaire Vaudois)
100 Deals associated with Melan-A analog peptide + Tyrosinase YMD peptide Vaccine Adjuvanted with CpG and Montanide(Centre Hospitalier Universitaire Vaudois)